Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Thrombosis Drugs Market to be Worth US$ 47 Bn by 2026, Says TMR

This image opens in the lightbox

News provided by

Transparency Market Research

06 Jul, 2018, 10:00 GMT

Share this article

Share toX

Share this article

Share toX

ALBANY, New York, July 6, 2018 /PRNewswire/ --

Transparency Market Research (TMR) titled "Thrombosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". According to the new report, the global thrombosis drugs market was valued at approximately US$ 20,012 Mn in 2017. It is projected to expand at a CAGR of more than 9.5% from 2018 to 2026.

     (Logo: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg )

The report suggests that the rise in geriatric population, which is more susceptible to thrombosis events, globally, is likely to boost the demand for thrombosis drugs during the forecast period. North America and Europe are likely to dominate the global thrombosis drugs market due to increase in awareness and rise in focus of key players on the development of new drugs in the market in these regions. Increasing penetration and rising prevalence of thrombosis events in emerging markets such as Japan, Hong Kong, and Taiwan are likely to boost the thrombosis drugs market in Asia Pacific at a CAGR of 9.0% from 2018 to 2026.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46293

Expansion of the Generic Drugs Industry to Hamper the Market 

The generic drugs industry has witnessed significant expansion in the last few years. Branded drugs of molecule such as heparin consistently lose market share due to the availability and continuous launch of generic version of the drugs. For example, recently, in January 2018, Aurobindo Pharma launched fondaparinux sodium injection, a generic version of Arixtra brand, which is utilized to prevent deep vein thrombosis, after its patent expired.

Low Molecular Weight Heparin to Lose Market Share 

The report offers detailed segmentation of global thrombosis drugs market based on drug class, indication, and distribution channel. Based on drug class, the factor Xa inhibitor drugs segment is estimated to account for a large share of the global market by the end of the forecast period. This is due to the increase in utilization of factor Xa inhibitor drugs for their advantages such as no drug monitoring is required after intake. Moreover, several studies have proved that factor Xa inhibitor drugs are effective in both deep vein thrombosis and pulmonary embolism and help reduce the rate of hospitalization after usage. The low molecular weight heparin segment is anticipated to lose market share during the forecast period, and is expected to decline from 14.7% held in 2017 to reach 5.9% by 2026. Patent expiry, availability of generic drugs, and increased preference toward oral formulation of drugs from injectable dose are factors that are likely to hamper this segment.

Request a Custom Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=46293

Pulmonary Embolism: Top Indication of Thrombosis Drugs 

In terms of indication, the pulmonary embolism segment is projected to hold for a dominant share of the global thrombosis drugs market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% from 2018 to 2026. Most companies are focused on developing low-cost drugs to serve the large pulmonary embolism patients pool across the globe; therefore, the pulmonary embolism segment is likely to account for a dominant share of the market. For example, the U.K-based pharmaceutical company, AstraZeneca, is developing a drug candidate called Brilliant Thales for the indication of cardiovascular events. The atrial fibrillation segment accounted for more than 27.0% share of the global thrombosis drugs market, in terms of value, in 2017. It is anticipated to expand at a substantial pace during the forecast period. The segment is likely to gain market share marginally to reach 27.8% by 2026.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=46293

The Market in North America to Expand at a Considerable Pace and Create Incremental Opportunity 

In terms of value, North America held a major share of the global market in 2017. This is due to the high health care expenditure and rise in awareness about the advantages of new oral anticoagulant drugs formulation in the U.S. Furthermore, several players such as Johnson & Johnson and Exithera Pharmaceutical have increased investment in research & development to develop advanced drugs to treat thrombosis. Thus, the presence of these players is projected to propel the thrombosis drugs market in North America at a rapid pace during the forecast period. Increase in incidence of age-related chronic conditions such as cancer and neurological illnesses increases thrombosis events in Asia Pacific. Moreover, improving economic conditions, rise in spending power, and better access to health care service fuels the market in Asia Pacific. Economic growth in countries such as Brazil is increasing research & development activities and expenditure on treatment in Latin America. These factors are likely to propel the thrombosis drugs market in Latin America. It is expected to expand at a CAGR of 9.0% from 2018 to 2026.

Request A Sample Of Thrombosis Drugs Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=46293

Bayer AG, Aspen Pharmacare Holdings Limited, and Boehringer Ingelheim GmbH to Dominate the Market 

The report also provides profiles of leading players operating in the global thrombosis drugs market. These include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, and Pfizer, Inc. Expansion of product portfolio through developing new products or by acquisition and licensing agreement to develop products is a key strategy adopted by several key players. For instance, in 2015, Isis Pharmaceuticals, Inc., entered into an exclusive license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Other key players are also adopting such strategies.

Popular Research Reports by TMR: 

  • Drug Discovery Outsourcing Market:  https://www.transparencymarketresearch.com/drug-discovery-outsourcing.html            
  • Drug Discovery Technologies Market:  https://www.transparencymarketresearch.com/drug-discovery-technologies.html

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Research Blog: https://theglobalhealthnews.com/

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.